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Summary
Acute graft-versus-host disease (aGvHD) is a major limitation to the use of allogeneic stem cell
transplantation for the treatment of patients with relapsed malignant disease. Previous work using
animals lacking secondary lymphoid tissue (SLT) suggested that activation of donor T cells in
SLT is critically important for the pathogenesis of aGvHD. However, these studies did not
determine if impaired migration into, and more importantly, out of SLT, would ameliorate
aGvHD. Here, we show that T cells from mice lacking Coronin 1A (Coro 1A−/−), an actin
associated protein shown to be important for thymocyte egress, do not mediate acute GvHD. The
attenuation of aGvHD was associated with decreased expression of the critical trafficking proteins
CCR7 and sphingosine 1 phosphate (S1P) receptor on donor T cells. This was mediated in part by
impaired activation of the canonical NF-κB pathway in the absence of Coro 1A. As a result of
these alterations, donor T cells from Coro 1A−/− mice were not able to initially traffic to SLT or
exit SLT after bone marrow transplantation. However, this alteration did not abrogate the GvL
response. Our data suggest that blocking T-cell migration into and out of SLT is a valid approach
to prevent aGvHD.
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Introduction
Acute graft-versus-host disease (aGvHD), a disease of selective epithelial damage, is a
severe complication of allogeneic stem cell transplantation (SCT). aGvHD occurs when
mature donor T cells recognize host alloantigen and initiate an immune response [1]. Work
from our group and others has shown that prior to tissue destruction, donor T cells must
migrate to secondary lymphoid tissue (SLT) where they are activated by host antigen
presenting cells (APCs) [2],[3]. Upon activation, donor T cells migrate to target organs,
primarily the liver, gastrointestinal tract, skin, and lung, where they cause tissue damage and
destruction characteristic of aGvHD [4].
The migration of lymphocytes to target organs involves selectins, integrins, and small
chemotactic proteins known as chemokines [5]. Chemokines bind G-protein coupled
chemokine receptors, which direct the migration of lymphocytes to target locations. Our
group has demonstrated the importance of migration of donor T cells and their interaction
with APCs in GvHD pathogenesis [6]. Furthermore the importance of SLT in GvHD
pathogenesis has been demonstrated, as animals lacking all SLT, including the spleen,
display markedly attenuated GvHD [3],[7]. However, despite multiple attempts, we have not
been successful in completely preventing aGvHD by blocking proteins important for T-cell
migration.
Numerous biological processes are regulated by the actin cytoskeleton and its associated
proteins. The Coronin family of actin-associated proteins has been shown to be involved in
cell migration, motility, and cell survival [8]. Coronins bind F-actin and interact with the
Arp2/3 complex [9], where they are critical in preventing nucleation of the branched F-actin
chain. Coronin 1A (Coro 1A) was the first of the seven family members identified. Coro 1A
is expressed primarily in hematopoietic cells and co-localizes with F-actin [10]. Expression
of Coro 1A in T lymphocytes is important for cytoskeleton rearrangement [11]–[13]. Several
groups have evaluated the function of immune cells from mice lacking Coro 1A. These
studies have indicated that T cells from Coro 1A knockout mice do not function normally,
although the mechanisms for this finding are still somewhat unclear and focus either on
proximal signaling events after activation of the T-cell receptor, and/or the induction of
apoptosis due to impaired generation of F-actin [12],[13]. In addition, a third group
evaluated the migration of thymocytes using mice with a point mutation in Coro 1A that led
to hypomorphic function for Coro 1A. They demonstrated impaired migration of thymocytes
from these mice in response to the signaling lipid sphingosine 1 phosphate, leading to
impaired thymic egress [14].
Reorganization of the actin cytoskeleton is an early response to chemokine receptor
stimulation [15]. Chemokine receptors have been shown to regulate signaling molecules that
are important for regulation of chemotaxis in lymphocytes and other cells [15]–[17].
Interestingly, the transcription factor nuclear factor kappa-light-chain enhancer of activated
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B cells (NF-κB) has been shown to be involved in the interaction between activation of T
cells and cytoskeleton alterations for mobility [18]. However, the mechanisms by which
these processes are linked remain unclear.
Currently, while multiple investigators have indicated that the complete absence of SLT
including the spleen eliminated aGvHD, it is not clear if aGvHD would be impacted by the
inability of donor T cells to egress from SLT. Previous work suggesting that the absence of
Coro 1A led to impaired migration led us to investigate the biology of aGvHD in a system
where T cells were impaired in their ability to enter or exit SLT. Here we show that unlike
our approaches targeting specific chemokine receptors, aGvHD is completely eliminated by
the inability of donor T cells to exit SLT and migrate to aGvHD target organs. These
alterations in migration of Coro 1A deficient cells were mediated by decreased expression of
the migratory proteins S1Pr1 and CCR7.
Results
Attenuated GvHD in multiple mouse models using Coro 1A−/− T Cells
The expression of Coronin 1A (Coro 1A) has been shown to be important for T-cell
trafficking [13]; however, the contribution of Coro 1A to disease pathophysiology remains
unclear [14]. To address the importance of Coro 1A in aGvHD, conventional T (Tcon) cells
cells from Coro 1A−/− or C57BL/6 (WT) donors supplemented with WT T cell depleted
bone marrow (TCD BM) cells were transplanted into lethally irradiated B6D2 F1 recipients.
As shown in Figure 1A, recipients of Coro 1A−/− Tcon cells had significantly improved
survival compared to recipients of WT donor Tcon cells. The clinical GvHD scores
confirmed survival data, demonstrating decreased clinical symptoms in recipients of Coro
1A−/− Tcon cells compared with WT Tcon cells recipients (Fig 1A). Recipients of Coro
1A−/− Tcon cells were fully donor by chimerism analysis by day 24 post-transplantion (data
not shown).
We further evaluated the importance of Coro 1A in aGvHD using a complete mismatch (B6
into BALB/c) transplant model. Previously, we were not able to completely prevent the
development of aGvHD targeting chemokine ligands or receptors using this model. Lethally
irradiated BALB/c recipients were administered Tcon cells from Coro 1A−/− or WT donors
with WT TCD BM. Similar to the haploidentical model, recipients of Coro 1A−/− Tcon cells
showed 100% survival until day 60 with minimal clinical manifestations of GvHD (Fig 1B).
Histopathology analysis of aGvHD target organs revealed decreased pathology in Coro
1A−/− recipients compared to WT recipients (Fig 2) with significant differences in the liver
and spleen and a trend for decreased pathology in the colon. Coro 1A−/− Tcon cells
recipients also displayed decreased organ cytokine production on day 14 with the values for
IFN-γ production in the liver and TNF and IFN-γ in the spleen being statistically significant
(Supporting Information Fig 1). Thus, the absence of Coro 1A from donor T cells led to a
profound decrease in the generation of aGvHD, even across a complete MHC mismatch.
Previous work suggested two potential mechanisms for diminished aGvHD in the absence of
Coro 1A. T cells deficient in Coro 1A may be impaired in activation mediated by
engagement of the T-cell receptor[12], or Coro 1A−/− T cells may be impaired in the ability
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to migrate in and out of lymphoid tissue[14]. Using cell proliferation dye or Brdu and cell
surface markers for activation, we evaluated these potential mechanisms in the post-
transplant setting at both day 3 and day 10 post-transplant. On day 3 post-transplant, there
was decreased proliferation of Coro 1A−/− Tcon cells in the spleen compared to WT Tcon
cells (Supporting Information Fig 2A). However, both CD4+ and CD8+ Coro 1A−/− T cells
exhibited increased CD69 expression, the earliest marker of T-cell activation. Other
activation markers were more varied, with increased CD62L expression by Coro 1A−/−
CD4+ T cells, but decreased CD62L expression of Coro 1A−/− CD8+ T cells. No differences
were found in CD25 or ICOS expression of CD4+ Tcon cells lacking Coro 1A. However,
there was decreased expression of CD25 and ICOS in Coro 1A−/− CD8+ Tcon cells on day 3
post transplant. On day 10 post-transplant, there was no difference in the proliferation of
donor WT versus Coro 1A−/− T cells isolated from the spleens of B6D2 recipients
(Supporting Information Fig 2B). To determine if the differences in activation markers were
due to intrinsic differences in T cell activation, we evaluated T-cell activation and
proliferation in vitro. Proliferation, measured by loss of carboxyfluorescein succinimidyl
ester (CFSE) and the generation of IFN-γ by T cells, was equivalent in WT and Coro 1A−/−
Tcon cells (data not shown). Thus, intrinsically, there was no difference in the activation or
proliferation of WT or Coro 1A−/− T cells.
Coro 1A−/− T Cells accumulate in gastrointestinal tract lymph nodes
Donor T cell activation requires the migration of donor cells into the spleen and secondary
lymphoid tissue of the host. One hypothesis for the inability to activate donor T cells from
Coro 1A null donors is the inability of those cells to migrate to SLT. To determine if
migration defects contributed to attenuated aGvHD using Coro 1A−/− donor T cells, we
crossed Coro 1A−/− mice with mice that constitutively express enhanced green fluorescent
protein (GFP). Using Coro 1A−/− GFP and WT GFP mice as donors, lethally irradiated
B6D2 F1 recipients were administered Tcon cells with WT (non-GFP) TCD BM. Three
days post-transplant, the MLN and PP were imaged by stereomicroscopy. Increased GFP
expression in the MLN was seen in WT GFP recipients as compared to Coro 1A−/− GFP
recipients, suggesting a delay in entry into lymph nodes by Coro 1A−/− T cells (Fig 3A).
Surprisingly, accumulation of Coro 1A−/− T cells was seen in the MLN and PP of B6D2
recipients 14 days post-transplantation, which continued through 28 days post-
transplantation (Fig 3A). Consistent with the accumulation seen in the MLN and PP, there
was a decrease in donor T cells in the liver and colon of Coro 1A−/− T cells as measured by
stereomicroscopy and GFP ELISA (Fig 3A and 3B). Migration defects displayed by
microscopy were complemented by blood analysis on day 14 post-transplantation that
revealed a decrease in circulating T cells in B6D2 recipients given T cells from Coro 1A−/−
GFP donors compared to WT GFP donors (Fig 3C). These data were consistent with
impaired entry and egress out of lymph nodes by Coro 1A−/− T cells.
To further confirm a defect in entry and egress from SLT, we performed an in vivo
competitive migration assay. Equal amounts of Coro 1A−/− GFP and WT Thy 1.1+ T cells
were injected into lethally irradiated B6D2 F1 recipients. 16 hours post-transplantation, the
MLN and inguinal lymph nodes (ILN) were harvested and analyzed by flow cytometry. As
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demonstrated in Figure 3D, even at this early time point, Coro 1A−/− T cells were markedly
less efficient in entering the MLN and ILN, as compared to WT T cells.
Decreased SLT ingress and egress receptors in Coro 1A−/− T cells
Numerous researchers have shown that the C-C chemokines receptor type 7 (CCR7) is
important for entry of T cells into secondary lymphoid organs[19]. Furthermore, data from
our laboratory have highlighted the importance of CCR7 in migration and GvHD
pathogenesis[3]. As Coro 1A−/− T cells displayed defects in lymph node entry, we
questioned whether Coro 1A−/− T cells had decreased CCR7 expression. To address this
question, real time PCR analysis was performed on freshly isolated Coro 1A−/− and WT
Tcon cells. Surprisingly, Coro 1A−/− Tcon cells expressed 2-fold less CCR7 than WT T cells
(Fig 4A). This decrease in CCR7 was further confirmed using an in vitro chemotaxis assay
to the CCR7 ligand, CCL19. Similar to the real time data results, Coro 1A−/− T cells
displayed impaired migration to CCL19 (Fig 4A). Responsiveness of Coro 1A−/− T cells to a
chemoattractant was confirmed using the supernatant from stimulated allogeneic dendritic
cells (Supporting Information Fig 2C).
In addition to the impaired migration into SLT, Coro 1A deficient T cells were unable to
egress from lymphoid tissue compared to WT T cells. Sphingosine-1 phosphate (S1P) is a
signaling sphingolipid that is produced by hematopoietic cells that has been shown to be
important for immune cell egress from SLT. Of the 5 S1P receptors, S1Pr1 has been shown
to be important for lymphocyte egress[20]. To evaluate S1P receptor expression in Coro
1A−/− T cells, we used quantitative real time PCR analysis. Coro 1A−/− Tcon cells displayed
decreased S1Pr1 expression compared to WT Tcon cells (Fig 4B). However, no difference
was found in the expression of the other S1P receptors (Fig 4B and data not shown) on Coro
1A deficient T cells. Additionally, we demonstrated a marked impairment in the migration
of Coro 1A−/− T cells to S1P compared to WT T cells indicating that this difference in
expression led to functional differences in response to the ligand (Fig 4B). These data
indicate that decreased CCR7 and S1Pr1 expression on Coro 1A−/− T cells correlated with
the decreased migration into and out of lymphoid organs.
Disruption of the NF-κB Pathway in the absence of Coro 1A
To investigate the mechanism for the diminished expression of CCR7 and S1Pr1 by Coro
1A−/− T cells, we analyzed signaling pathways in conventional T cells. Regulation of the
integrity of the actin cytoskeleton is important for numerous signaling pathways including
the NF-κB and the mitogen-activated protein kinase (MAPK) pathways [21],[22]. Decreased
phosphorylated p65 was found under stimulating and non-stimulating conditions in Coro
1A−/− Tcon cells (Fig 5). Alterations in the NF-κB pathway were specific to the canonical
pathway, as no changes in the p100 subunit were observed in WT or Coro 1A−/− Tcon cells
(Fig 5). We found no difference in activation under stimulating or non-stimulating
conditions of the p38 MAPK protein in Coro 1A null compared to WT T cells as evaluated
by western blot (Supporting Information Fig 3). These data suggest that the expression of
CCR7 and S1P1r in Coro 1A−/− Tcon cells are correlated with impaired activation of the
canonical NF-κB pathway [23].
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Maintenance of the GvL response using Coro 1A−/− Tcon cells
T cells responsible for the pathogenesis of aGvHD are also responsible for the graft-versus-
leukemia effect (GvL) that eliminates residual tumor cells in recipients minimizing the
probability of relapse. Knowingly, we investigated whether Coro 1A−/− Tcon cells maintain
GvL effects. WT TCD BM with luciferase expressing A20 B cell lymphoma cells were
transplanted into lethally irradiated B6D2 F1 recipients with either Coro 1A−/− Tcon cells or
WT Tcon cells. B6D2 recipients of Coro 1A−/− T cells survived until completion of the
experiment with no tumor infiltration, while B6D2 recipients given A20 cells with bone
marrow alone succumbed to death by tumor infiltration 24 days post-transplantation (Fig 6).
Mice that received WT Tcon cells succumbed to death by aGvHD, prior to infiltration of
tumor cells (data not shown). These data demonstrate that in addition to attenuated aGvHD,
Coro 1A−/− Tcon cells maintained the beneficial GvL response.
Discussion
The contribution of T-cell migration to aGvHD pathogenesis has been well studied [3],[24].
Our group and others have shown that chemokines and their receptors, integrins, and
selectins all play a critical role in T cell migration during aGvHD [6],[25],[26]. Here we
extend these findings, demonstrating that cells deficient in the F-actin associating protein,
Coronin 1A, are markedly impaired in their ability to mediate acute GvHD due to
accumulation in secondary lymphoid organs and the inability to egress from these organs.
The diminished aGvHD seen using T cells deficient in Coro 1A correlated with decreased
tissue pathology in recipient mice. In vitro proliferation and cytokine production by Coro
1A−/− Tcon cells was comparable to WT Tcon cells; while decreased proliferation by Coro
1A−/− Tcon cells was seen in vivo and markers of early activation were comparable to that
of WT Tcon cells. Lastly, we showed that signaling cascades downstream of the TCR are
impaired in the absence of Coro 1A. The reduction in the expression and function of CCR7
and S1Pr1 correlated with impaired migration and activation of the canonical NF-κB
pathway. Thus, these data suggest that one method of blocking acute GvHD is to prevent the
migration of donor lymphocytes into and out of SLT.
The function of SLT in the biology of aGvHD has been studied elegantly by several
different investigators predominately using genetic approaches. These data indicated that
SLT was critical to the induction of acute GvHD [7],[27]. However, this activity was
redundant, with all secondary lymphoid tissue and the spleen capable of initiating acute
GvHD. Thus, it has not been clear if this process would be amenable to clinical intervention.
Here, we show that acute GvHD can be prevented by blocking the migration of T cells into
and out of secondary lymphoid tissue, which correlated with the impaired function of CCR7
and S1P1r. Clinically this is important as both CCR7 and S1Pr1 are drugable targets. S1P
agonists are currently available for the treatment of patients with multiple sclerosis [28]. Our
group has initiated a significant screening process to identify inhibitors of CCR7. Our data
would suggest that a combination approach using these inhibitors would have significant
activity in preventing acute GvHD.
Several laboratories, but most specifically the Cyster laboratory, have shown in a number of
elegant manuscripts the requirement for S1Pr1 expression on T cells for migration of those
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cells out of lymph nodes via the efferent lymph system [29]. The function of S1Pr1 is not
limited to lymphocyte migration, as S1Pr1 has also been shown to be important in
inflammatory responses in other immune cells [30]. Real time PCR analysis of Coro 1A−/−
T cells confirmed decreased expression of S1Pr1 but not other S1P receptors on Coro 1A−/−
T cells. Interestingly, our group has previously evaluated the function of FTY720, an agonist
of S1P that, in models, prevents acute GvHD pathogenesis [31]. While we were able to
indicate that FTY720 administration could abrogate acute GvHD, this did not correlate with
impaired egress of donor T cells from SLT. Thus, the current data are the first to indicate
that egress out of SLT is important for the function of donor T cells during acute GvHD
[32].
The importance of the chemokine receptor CCR7 in T lymphocyte migration has been well
established. Data from our group demonstrated impaired donor T cell migration to
secondary lymphoid organs of donor T cells lacking CCR7 [3]. However, in our previous
work, we were unable to completely block acute GvHD in the major mismatch model by
infusing T cells lacking CCR7. This indicates that the profound decrease in aGvHD found
after the infusion of T cells lacking Coro 1A in BALB/c recipients is not solely due to the
absence of CCR7. This would further suggest that blocking migration into and out of
secondary lymphoid tissue has a more profound effect than blocking the initial interaction of
donor T cells with APCs.
Blocking of GvHD that mitigates the GvL response is not a successful strategy for
improving allogeneic SCT. Tumor cell elimination was seen in Coro 1A−/− Tcon cells
recipients, demonstrating maintenance of GvL response by Coro 1A−/− Tcon cells in a
lymphoma model. Importantly mice that received WT Tcon cells with tumor cells
succumbed to aGvHD before tumor infiltration could occur. These results further highlight
the benefits of Coro 1A−/− Tcon cells in allogeneic SCT. It should be noted that naïve T
cells deficient in Coro 1A may have a reduced anti-leukemic response due to a decreased
ability to exit SLT and traffic to the bone marrow. However previous investigations have
found that antigen-specific T cells that traffic to the bone marrow can be primed by bone
marrow resident DCs [33]. This priming, even in the absence of secondary lymphoid tissue,
generates cytotoxic T cells that can provide an anti-tumor response and immunologic
memory. Thus, we believe that blocking the migration of naïve T cells in and out of SLT
may not hinder the activation of antigen-specific T cells in the bone marrow.
In summary, we have found that the absence of Coro 1A in donor T cells markedly
diminished the incidence and severity of acute GvHD. We demonstrate that Coro 1A−/− T
cells have impaired migration into and out of secondary lymphoid tissue, which correlated
with diminished expression of CCR7 and S1P1r. These data indicate that approaches that
prevent the migration of T cells into and out of secondary lymphoid tissue with maintenance
of GvL response may significantly impact the occurrence of acute GvHD.
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C57BL/6J (H2b) (termed WT), BALB/c, and C57BL/6J x DBA/2 F1 (termed B6D2) were
purchased from The Jackson Laboratory. The generation of enhanced green fluorescent
protein expressing (GFP) C57BL/6 mice has been described previously [4]. Coro 1A
deficient (Coro 1A−/−) C57BL/6 mice were obtained from Niko Foger and generated as
described [12],[34]. Coro 1A−/− GFP mice were generated by crossing Coro 1A−/− mice
with GFP C57BL/6 mice. All experiments were performed in accordance with protocols
approved by the University of North Carolina Institutional Animal Care and Use Committee.
Transplantation Models
T cell depleted bone marrow (TCD BM) was prepared as previously described [35]. CD25
depleted T cells were prepared using a total T cell isolation kit (Cedarlane Laboratories)
followed by antibody depletion and magnetic cell separation as previously described [3].
The day prior to transplantation, recipient mice received either 950 cGy (B6D2) or 800 cGy
(BALB/c) of total body irradiation. For B6 to B6D2 or B6 to BALB/c transplants, recipients
were intravenously injected with either 4 × 106 T cells and 3 × 106 TCD BM cells, or 5 ×
105 total T cells and 5 × 106 TCD BM cells, respectively, unless otherwise noted.
Histopathology analyses were prepared as previously described and analyzed by one of us
(A.P.M.) blinded to the genotype of the donor [36].
Stereomicroscopy
Organs from anesthetized animals were imaged with a Zeiss Stereo Lumar V12 microscope
with GFP bandpass filter (Carl Zeiss MicroImaging, Inc.) at room temperature. AxioVision
(Carl Zeiss) software was used to determine GFP intensities. WT GFP and Coro 1A−/− GFP
recipient organs were imaged using the identical magnification (mag) and exposure (exp)
times for each time point. Day +3: PP-exp 976ms, mag 32X MLN-exp 2.5s, mag 15X Day
+14: PP-exp 1s, mag 30X MLN-exp 1s, mag 20X Colon-exp 4s, mag 13X Liver-exp 2s,
mag 40X Lung-exp 4s, mag 18X Day +28: PP-exp 750ms, mag 30X MLN 600ms, mag 20X
Colon-exp 3s, mag 13X Liver-exp 3s, mag 40X
Organ GFP Quantification
Organs from recipient animals were homogenized and absolute GFP levels determine by
ELISA (Cell Biolabs). Detailed experimental procedures were conducted as described
previously [3].
In Vivo Competitive Migration Assay
CD25 negative total T cells were isolated as described above from Coro 1A−/− GFP and Thy
1.1+ WT mice. Recipient B6D2 mice were injected intravenously with equal amounts of
Coro 1A−/− GFP and WT Thy 1.1+ donor T cells. 16 hours post transplantation, the
mesenteric lymph node, inguinal lymph node, and spleen were harvested, stained, and
analyzed by flow cytometry.
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Real Time PCR Analysis
Real time PCR was performed as previously described [36]. Gene expression was
normalized to the housekeeping gene GusB before determining fold induction using ΔΔCt
method. Taqman expression assay probes for S1Pr1, S1Pr3, S1Pr5, and CCR7 were
purchased from Applied Biosystems.
Chemotaxis Analysis
Conventional T cells (Tcon cells) were isolated using Cedarlane total T cell isolation kit
following by antibody depletion coupled with negative selection. Following isolation the
cells were washed twice with PBS. 5 × 105 or 2 × 105 total T cells in 100μL were added to
the upper chamber of a PVP treated 5μM pore polycarbonate membrane inside of a
ChemoTx® chamber system (Neuroprobe). The bottom chamber was filled with the
indicated concentrations of sphingosine-1 phosphate (Sigma) or C-C motif chemokine 19
(Peprotech) and incubated for 3 hours at 37°C. CyQuant cell quantification kit (Invitrogen)
was used to determine cell migration from the upper chamber to the lower chamber.
Western Blot Analysis
Freshly isolated Tcon cells were lysed in RIPA (Invitrogen) buffer supplemented with
protease and phosphatase inhibitors (Roche). Lysates were separated by SDS-PAGE on a 4–
12% Bis-Tris gel (Life Technologies), transferred onto a nitrocellulose membrane and
incubated in 5% non-fat dry milk to block non-specific binding. Membranes were incubated
with the following antibodies purchased from Cell Signaling Technology: phospho NF-κB
p65 (Ser536), NF-κB2 p100/p52. GAPDH antibody was purchased from Santa Cruz
Biotechnology. Proteins were detected using anti-rabbit IgG HRP (Promega) and the ECL
western blotting detection kit according to manufacturer’s instructions (GE Healthcare).
In vivo Proliferation
Lethally irradiated B6D2 recipients were transplanted with equal amounts of Coro 1A−/−
GFP and WT Thy 1.1+ donor total T cells concurrently with WT TCD BM. Ten days post
transplantation recipient mice were injected intraperitoneally with BrdU labeling reagent
(Invitrogen). Four hours after injection the spleens were harvested and stained for BrdU
(Invitrogen) and the following antibodies from eBioscience: CD45, CD44, CD62L, Thy 1.1.
Mixed Lymphocyte Reaction
Equal amounts of Coro 1A−/− or WT T cells and irradiated B6D2 splenocytes were cultured
in RPMI complete for 24 or 48 hours. For activation the cells were stained with the
following antibodies from eBioscience: CD62L, CD44, CD69. For cytokine production the
cells were permeabilized using the BD Cytofix/cytoperm plus kit and stained with TNF or
IFN-γ antibodies also purchased from eBioscience. Cells were analyzed by flow cytometry
using FlowJo analysis software.
Proliferation Assay
Coro 1A−/− or WT T cells were labeled with 10μM carboxyfluorescein succinimidyl ester
(CFSE) (Invitrogen). Equal amounts of labeled Coro 1A−/− or WT Teffs and B6D2 irradiated
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splenocytes were cultured in RPMI complete for 24 or 48 hours. Following harvest the cells
were stained with CD4 and CD8 antibodies (eBioscience). Proliferation was determined by
flow cytometry using the FlowJo analysis software.
GvHD Scoring
Mice were observed twice weekly for clinical GvHD signs and symptoms based on a
previously established clinical scoring system [37].
Statistical Analysis
Survival curves were constructed using the Kaplan Meier method. Median survival was
determined using the log rank test. Continuous values including cytokine levels, total cell
numbers, clinical scoring and GFP expression were determined using two-tailed Student’s t-
test. P-values less than 0.05 were considered significant. Error bars represent standard error
of the mean.
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Figure 1. Attenuated GvHD in the absence of Coro 1A
(A) 4 × 106 Coro 1A−/− T cells (Tcon cells) or WT Tcon cells supplemented with 3 × 106
WT T cell depleted bone marrow cells (TCD BM) were injected into lethally irradiated
B6D2 recipients. Recipients were then monitored for survival (left) and GvHD score (right).
Data are shown as mean + SEM of n=14 for Coro 1A−/− and WT Tcon cells recipients, n=4
for bone marrow only. Data are pooled from 3 individual experiments. (B) Lethally
irradiated BALB/c recipients were infused with 5 × 105 Coro 1A−/− or WT Tcon cells with 5
× 106 WT TCD BM cells. Following transplantation mice were monitored for survival (left)
and clinical GvHD development (right). Data are shown as mean + SEM of n=19 for Coro
1A−/− and WT Tcon cells recipients, n=6 for bone marrow only. Data are pooled from 3
individual experiments. *p<0.001, two tailed Student’s t-test.
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Figure 2. Histopathology of B6D2 recipients after transplantation of Coro 1A−/− or WT Tcon
cells
Lethally irradiated B6D2 recipients were transplanted with 4 × 106 Coro 1A−/− or WT Tcon
cells with 3 × 106 WT TCD BM. Fourteen days post transplantation organs were harvested
for pathology analyses. Data are shown as mean + SEM of n=6 for Coro 1A−/− and WT
recipients, n=4 for bone marrow controls, from a single experiment representative of 2
performed. *p<0.05, two tailed Student’s t-test.
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Figure 3. Delayed entry and impaired egress in secondary lymphoid organs by Coro 1A−/− Tcon
cells
Coro 1A−/− GFP or WT GFP Tcon cells supplemented with WT TCD BM were infused into
lethally irradiated B6D2 recipients. (A) Migration of the cells to the liver, colon, mesenteric
lymph node and Peyer’s patches was determined using stereomicroscopy. Images were
collected 3, 14 and 28 days post transplantation. Left panels display GFP expression while
right panels reflect intensity. Data shown are representative of 6-8 B6D2 recipients given
either Coro 1A−/− GFP or WT GFP Tcon cells. (B) GFP ELISA was used to quantify
expression in B6D2 recipients transplanted with Coro 1A−/− GFP or WT GFP Tcon cells 14
days post transplantation. Data shown are mean + SEM of n=5 for WT GFP and Coro 1A−/−
GFP recipients from a single experiment representative of 3 experiments performed.
*p<0.05, two tailed Student’s t-test. (C) Peripheral blood was collected from WT GFP or
Coro 1A−/− GFP Tcon cells recipients 14 days post transplantation. T cells in the blood were
evaluated by flow cytometry using CD4 and CD8 surface markers. Cells were gated first by
GFP positive expression then CD4 and CD8 expression. Data are shown as n=4 for Coro
1A−/− GFP recipients, n=3 for WT GFP recipients from a single experiment. (D) In vivo
competitive migration using Coro 1A−/− GFP and WT (Thy 1.1+) cells was performed as
detailed in the Materials and methods. Flow cytometry analysis of Coro 1A−/− GFP and WT
(Thy 1.1+) Tcon cells were conducted on the spleen (data not shown) and pooled mesenteric
and inguinal lymph nodes (representative sample shown) 16 hours post transplantation. Data
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shown are representative of n=3 for Coro 1A−/− GFP or WT (Thy 1.1+) Tcon cells
recipients, from an experiment performed twice.
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Figure 4. Decreased receptor expression and impaired chemotaxis in the absence of Coro 1A
(A) Expression of CCR7 and chemotaxis to CCL19 of WT or Coro 1A−/− Tcon cells was
determined by real-time PCR. (B) Real time expression of S1Pr1 and S1Pr5 and chemotaxis
to S1P in WT and Coro 1A−/− Tcon cells is also shown. *p<0.05, two tailed Student’s t-test.
Data are shown as mean + SEM of three experiments of n=9 WT and n=9 Coro 1A−/− Tcon
cells.
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Figure 5. Decreased activation of NF-κB in Coro 1A−/− Tcon cells
3 × 106 WT or Coro 1A−/− Tcon cells were stimulated for 30 minutes with either 20ng/mL
of TNF or 20ng/mL of anti-CD3 and 10ng/mL of anti-CD28. Tcon cells were harvested and
analyzed by western blot for p100 and phospho p65 expression. GAPDH was used as a
loading control. Data shown are representative of 3 individual experiments.
Fulton et al. Page 18






















Figure 6. GvL response using Coro 1A−/− Tcon cells
1 × 104 luciferase-expressing A20 B cell lymphoma cells supplemented with WT TCD BM
were injected into lethally irradiated B6D2 recipients. Mice were also injected with either
Coro 1A−/− or WT Tcon cells. Mice were monitored for survival and tumor infiltration via
luciferase imaging using the IVIS® Kinetic Optical System. Data shown are representative
of n=12 for Coro 1A−/− and n=9 for A20 + bone marrow. Data are pooled from three
individual experiments.
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